ArticleBMC pulmonary medicine2020
COVID-19 or clinical amyopathic dermatomyositis associated rapidly progressive interstitial lung disease? A case report.
Article in BMC pulmonary medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review.Rheumatology and therapy · 2026Pooled it
- Baricitinib and Pulse Steroids Combination Treatment in Hyperinflammatory COVID-19: A Rheumatological Approach in the Intensive Care Unit.International journal of molecular sciences · 2024Article
- Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review.Rheumatology international · 2022Review
- Acute neuromuscular syndromes with respiratory failure during COVID-19 pandemic: Where we stand and challenges ahead.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2022Review
- Clinical course of idiopathic inflammatory myopathies in COVID-19 pandemic: a single-center experience.Future virology · 2022Article
- COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era.Journal of the peripheral nervous system : JPNS · 2022Review
- Long COVID from rheumatology perspective - a narrative review.Clinical rheumatology · 2022Review
- Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review.Journal of inflammation research · 2022Article
- Dermatomyositis-lupus overlap syndrome complicated with cardiomyopathy after SARS-CoV-2 infection: A new potential trigger for musculoskeletal autoimmune disease development.Clinical case reports · 2021Article
- Comprehensive work-up is warranted for patients with severe COVID-19 and muscle weakness including respiratory muscles.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2021Article
- Reply to "Comprehensive work-up is warranted for patients with severe COVID-19 and muscle weakness including respiratory muscles".Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2021Article
- COVID-19 Disease and Dermatomyositis: A Mini-Review.Frontiers in immunology · 2021Review
- Prevalence of cutaneous manifestations and myositis-specific antibodies in COVID-19 patients and Anti-PL7 antibodies association with pulmonary radiological severity: A retrospective study.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease 2019 (COVID-19) has reach pandemic proportions globally. For patients with symptoms of fever and cough accompanied by rapid lung damage progression, COVID-19 needs to be distinguished from interstitial lung disease (ILD) attributed to connective tissue disease (CTD), especially dermatomyositis (DM)/clinical amyopathic dermatomyositis (CADM) associated rapidly progressive interstitial lung disease (RP-ILD). CASE PRESENTATION: We report a case of a woman observed with fever, cough, and rapid lung damage during the epidemic. The patient had a suspicious epidemiological history, and her chest CT scans showed lung damage similar to that caused by COVID-19, but anti-Ro52 antibody was strongly positive. She was diagnosed with CADM associated RP-ILD and died 1 month later.
conclusionsDuring the COVID-19 epidemic, it is critical to carefully assess patients with CTD related ILD, especially RP-ILD associated with CADM. Repeated nucleic acid tests for COVID-19 are necessary to achieve accurate case diagnosis. High-resolution CT (HRCT) of the chest is presently deemed an inefficient technique to distinguishing between COVID-19 and CADM associated RP-ILD. The characteristic rashes of dermatomyositis require careful observation and can often provide diagnostic clues. For patients with CADM, a high titers of anti-Ro52 antibody may be related to the pathogenesis of RP-ILD, suggesting a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.